key: cord-0706926-et4yuiup authors: Werfel, Stanislas; Jakob, Carolin E. M.; Borgmann, Stefan; Schneider, Jochen; Spinner, Christoph; Schons, Maximilian; Hower, Martin; Wille, Kai; Haselberger, Martina; Heuzeroth, Hanno; Rüthrich, Maria M.; Dolff, Sebastian; Kessel, Johanna; Heemann, Uwe; Vehreschild, Jörg J.; Rieg, Siegbert; Schmaderer, Christoph title: Development and validation of a simplified risk score for the prediction of critical COVID‐19 illness in newly diagnosed patients date: 2021-08-10 journal: J Med Virol DOI: 10.1002/jmv.27252 sha: 42709210b3a9c3089dd61c3b83dc1e05a905b02c doc_id: 706926 cord_uid: et4yuiup Scores to identify patients at high risk of progression of coronavirus disease (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), may become instrumental for clinical decision‐making and patient management. We used patient data from the multicentre Lean European Open Survey on SARS‐CoV‐2‐Infected Patients (LEOSS) and applied variable selection to develop a simplified scoring system to identify patients at increased risk of critical illness or death. A total of 1946 patients who tested positive for SARS‐CoV‐2 were included in the initial analysis and assigned to derivation and validation cohorts (n = 1297 and n = 649, respectively). Stability selection from over 100 baseline predictors for the combined endpoint of progression to the critical phase or COVID‐19‐related death enabled the development of a simplified score consisting of five predictors: C‐reactive protein (CRP), age, clinical disease phase (uncomplicated vs. complicated), serum urea, and D‐dimer (abbreviated as CAPS‐D score). This score yielded an area under the curve (AUC) of 0.81 (95% confidence interval [CI]: 0.77–0.85) in the validation cohort for predicting the combined endpoint within 7 days of diagnosis and 0.81 (95% CI: 0.77–0.85) during full follow‐up. We used an additional prospective cohort of 682 patients, diagnosed largely after the “first wave” of the pandemic to validate the predictive accuracy of the score and observed similar results (AUC for the event within 7 days: 0.83 [95% CI: 0.78–0.87]; for full follow‐up: 0.82 [95% CI: 0.78–0.86]). An easily applicable score to calculate the risk of COVID‐19 progression to critical illness or death was thus established and validated. The first human cases of coronavirus disease (COVID-19) were described in December 2019 in Wuhan. 1 COVID-19 subsequently developed into one of the most disastrous pandemics experienced in our civilization since the Spanish flu at the beginning of the 20th century. 2, 3 The exponential spread of the disease-causing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as happened throughout Europe during the first wave of the pandemic, can result in excessive hospital overload and a shortage of healthcare resources, which may negatively impact patient outcomes. 4 This experience underpinned the importance of an effective process to allocate limited healthcare resources to the COVID-19 patients most likely to benefit. To guarantee functional patient care, disease severity assessment for patients presenting at the emergency department (ED) may prove useful and guide frontline physicians in the decision-making process. A considerable number of patients deteriorate rapidly following hospital admission and require transfer to the intensive care unit (ICU). Conversely, the clinical conditions of other COVID-19 patients improve rapidly. Therefore, a prediction model can guide physicians in determining whether patients require hospital admission or can be followed up in outpatient care. A risk assessment score may additionally be a useful tool to estimate the individual risk-benefit trade-off for therapeutic interventions. This study aimed to develop a simplified risk prediction model based on clinical and demographic characteristics and laboratory findings at the time of COVID-19 diagnosis to estimate the risk of clinical deterioration to critical illness. We used data from the Lean European Open Survey on SARS-CoV-2 (LEOSS) project, a prospective European multicenter cohort study. 5 2 | METHODS This analysis included patients who received care at a LEOSS partner site (inpatient or outpatient) beginning March 16, 2020 . Cases documented in the LEOSS registry up till August 6, 2020 comprised the initial cohort, which was split into derivation and validation sets. Cases entered from August 7, 2020 to November 18, 2020 comprised the additional test sets (Figure 2A ). The design of the LEOSS study and data acquisition was previously described. 5 Data were recorded anonymously, and no patient-identifying data were stored. The requirement for written informed consent was therefore waived. Continuous parameters were categorized. To ensure anonymity at all stages of the analysis process, an individual LEOSS Scientific Use File (SUF) was created, which is based on the LEOSS public use file (PUF) principles, as described previously. 6 Following these principles, a minor portion of patients and variable values were removed from the data set and set to missing values to ensure anonymization. Approval for LEOSS was obtained by the applicable local ethics committees of participating centers, and the study was registered at the publicly accessible German Clinical Trials Register (DRKS, No. DRKS00021145). All predictors included in the stability selection are listed in Tables 1 and S1 . We predefined a combined endpoint of progression to critical disease or COVID-19-related death. The definitions of the disease phases are summarized in Figure 1 All analyses were performed using R (version 3.6.3). Random forest (RF) analyses (including missing value imputations and individual Boruta stability selection steps) were calculated using the "random-ForestSRC" package by Ishwaran and Kogalur. 7 Among the available baseline variables of the LEOSS data set (≈170 predictors), we selected those with <50% missing values among the combined derivation and validation data set (n = 1946 patients, Figure 2 ), with the exception of troponin T (52% missing) and pancreatic lipase (56% missing). This resulted in a total of 104 predictors (Tables 1 and S1 ). The time-to-event data in the anonymized LEOSS cohort was grouped for patients experiencing an event at ≥8 days after study inclusion, the time variable was coded accordingly as 1-7 days and ≥8 days, resulting in eight bins for the time variable (Table S1 ). These were used for the time-to-event approaches: random survival forest and Cox models, and for C-index calculation. Continuous predictors were binned as value ranges in the LEOSS cohort due to anonymization, and the ranges were coded as consecutively increasing integers. We performed RF missing value imputation using multivariate Abbreviations: 7d, event (critical phase or COVID-19-related death) within 7 days of diagnosis; CRP, C-reactive protein; LDH, lactate dehydrogenase; LN, laboratory normal range, "x" indicates multiples of the upper limit of the normal range; PCT, procalcitonin; Test, f., full test set (as shown in Figure 2 ); Test, l., limited test set (as shown in Figure 2 ). F I G U R E 1 Definition of COVID-19 disease phases in the LEOSS registry. Patients were assigned to the highest phase for which at least one characteristic was fulfilled. ALT, alanine transaminase; AST, aspartate transaminase; INR, international normalized ratio of prothrombin time; PaO 2 , partial pressure of oxygen in arterial blood; qSOFA, quick sequential organ failure assessment score; sO 2 , blood oxygen saturation; ULN, upper limit of normal We performed a split into a derivation and validation cohort with similar characteristics based on the following predefined potential Finally, the regression coefficients were divided by the smallest value and rounded to the next integer. Two-sided p values for the binomial ridge penalized coefficients were obtained as suggested by Cule et al., 13 by repeating the ridge regression procedure on a data set with randomly permuted outcomes 1000 times (using equal numbers of the 20 imputed data sets). The area under the receiver operating characteristics curve (AUC) and Harrell's C-indices were calculated using linear predictors from the binomial and Cox ridge-penalized regression models or outof-bag predictor estimates for the RF approaches. The 95% confidence intervals (CIs) for AUC and C-indices were calculated using 1000 bootstraps of patients' scores using equal contributions from the imputed data sets. Important characteristics of the LEOSS cohort were previously described. 5 More diagnosed SARS-CoV-2 cases were available for the current analysis compared with the previous report (2969 in the first data set, patients from the first wave of the pandemic, and 1233 patients in the second test set; Figure 2 ). 5 Based on the predefined disease phase (Figure 1 ) and the availability of laboratory values, a total of 1946 patients were included in the first round of analysis and assigned to derivation and validation groups with similar characteristics ( Figure 2 ). Important characteristics are summarized in Table 1 , with a summary of the remaining predictors provided in Table S1 . The age distribution in the first data set was centered, with approximately equal contributions of patients aged ≤65 and >65 years. There were more men than women (55%-59% vs. 41%-45%). At least 56% presented with known CV comorbidity. The incidence of the combined endpoint, critical phase or COVID-19-related death (Table 1) . From the second test set (patients entered into the registry after the first data export for score derivation), 682 patients fulfilled the selection criteria. This set largely consisted of patients diagnosed after June 2020 ( Figure 2 ). Compared with the derivation/validation cohorts, the patients were younger (60% ≤65 years) and more were diagnosed during an uncomplicated phase (72% vs. 64%-68%). Consequently, the event rate was lower, with only 10% experiencing an event within 7 days of diagnosis and 12% during follow-up (Table 1 ). Both the derivation and validation data sets consisted almost exclusively of patients receiving inpatient care. We performed Boruta variable stability selection using RF for classification, resulting in the selection of 5 (out of 104) predictors (Table 2) . These were CRP, disease phase, age, serum urea, and D-dimer levels ( Figure S1A ). Interestingly, including only these five predictors in a logistic regression model achieved results almost on par with the full set of variables ( Table 2 , "RF Boruta," binomial ridge, median AUC = 0.81 in the validation cohort). We additionally performed a Boruta stability selection using an RSF approach. Twenty-four predictors were retained, with the five predictors from RF Boruta among the most important variables ( Figure S1B ). Increasing the number of predictors from 5 to 24 had a minor impact on the model's performance in the validation data set as measured by Harrell's C-index (median C-index: 0.76 vs. 0.77, respectively; Table S2 ). Based on the encouraging results and simple interpretability, we used the coefficients obtained in the binomial ridge regression model with five predictors (Table 3) to derive an additive score to predict COVID-19 progression to the critical phase or death. The score is listed in Note: Initial derivation and validation analyses were performed on the respective data sets (n = 1297 and 649, respectively) as summarized in Figure 2 . As indicated, the final score was additionally independently validated on the full and the limited test sets (n = 682 and 219, as described in Figure 2 ). Indicated are the median values and the full range for the imputed data sets (in brackets). AUC values were calculated for an event within 7 days of diagnosis ("7d") and for all time points ("all"). 95% confidence intervals (95% CI) were calculated for score predictions using bootstrapping with equal contributions of the imputed data sets. Results of the performance of the final score (median AUC and 95% CI) in the resprective validation and test datasets are highlighted in bold. Abbreviations: AUC, area under the receiver operating characteristic (ROC) curve; imp., imputation; N pr., number of predictors in the model; pr., predictors; RF, random forest for classification. Note: Indicated are β coefficients from binomial ridge regression (outcome: event within 7 days) and the resulting weights per step increase in the respective predictor group (all groups are listed in Table 4 ). p values were calculated using ridge regression on the derivation data set with permutations of the outcome. Abbreviation: CRP, C-reactive protein. both the derivation and validation data sets (median AUC in validation data set for events within 7 days of diagnosis: 0.81, 95% CI: 0.77-0.85; for all events, 0.81, 95% CI: 0.77-0.85; Table 2 ). Interestingly, the simplified score yielded a similar performance as a Cox regression or an RSF approach with both 5 and 24 predictors as measured by Harrell's C-index (median C-index of 0.76, 95% CI: 0.73-0.80 in the validation cohort; Table S2 ). We used the second test set of patients whose data were entered into the registry after the initial data export (n = 682 patients, "full test set" in Figure 2 ) as an independent prospective validation group. To further reduce the impact of missing values on the estimation of score performance, we additionally removed patients from centers with >20% missing values for D-dimer, the variable with the most missing values (42%-47% missing). Centers that enrolled <5 patients were also excluded, which produced an additional "limited test set" (n = 219 patients; Figure 2 ). This data set had few missing values (CRP, 1%; serum urea, 2%; D-dimer, 7% missing; Table S2 ). Depending on the clinical application, different cut-off values may be considered. Therefore, we provide the predictive metrics of the score, such as sensitivity, specificity, and positive and negative predictive values (PPV and NPV) versus the cut-off (Figure 3 ), as well as the absolute event risks for specific score values ( Figure S2 ). Apart from the discriminative performance, we observed good calibration with a slope ranging from 0.949 to 1.113 in the different validation/test data sets ( Figure S3) . Interestingly, the Brier score was tendentially smaller in the "full test" compared to the validation data set (0.076-0.091 vs. 0.106-0.124, respectively; Figure S3 ), mirroring the tendency toward better discriminative performance in this data set (Tables 2 and S2 ). Calibration-in-the-large for the "full test" set, which yielded a lower event per case rate, was similar to that in the validation set for an event within 7 days (intercept: −0.160 vs. −0.174, respectively), but lower for all events (intercept: −0.314 vs. 0.010, respectively, potentially reflecting the differences in event rates between the cohorts). One method for selecting a cut-off is to optimize the modified Youden's J. 14 For the proposed score, the optimal J in the combined validation and full test data set was at a cut-off of ≥17, both for predictions at 7 days after diagnosis and for all events. Applying this cut-off, on average, 69% of patients were predicted not to progress to critical illness (Table 5 , combined validation/test data set) at an NPV of 95% for 7 days after diagnosis and an NPV of 94% for full follow-up. Patients with scores at or above this threshold had~3-fold increased odds of experiencing an event, whereas patients below this threshold had~3-fold decreased odds as measured by the respective likelihood ratios (Table 5 ). We describe the derivation and validation of a COVID-19 risk score for the prediction of the combined endpoint of critical disease or COVID-19-related death using five predictors. We derive the score in an untargeted manner by selecting the most stable predictors among over 100 available at baseline in the LEOSS registry in an RF approach and using regularized regression to calculate the coefficients. Maximum score 38 Abbreviations: CRP, C-reactive protein; LN, laboratory normal range, "x" indicates multiples of the upper limit of the normal range. WERFEL ET AL. Another important consideration is the generalizability of mortality as an outcome in patient stratification. Case fatality rates differ widely across countries, 22 perhaps partly attributed to countryspecific differences in the clinical management of COVID-19 patients and to resource availability during the first wave of the pandemic. 4 This may limit generalizability and potentially require an update to existing scores for mortality prediction, 23 as care providers gain experience with COVID-19 management and the strain on hospitals is reduced. A previous review on COVID-19 prognosis scores came to an overall negative assessment of the potential bias of these scores, which discouraged their use. 15 We successfully confirmed the performance of our score in an independent test set, consisting of the majority of COVID-19 cases diagnosed after the first wave of the pandemic. An important contributor to the predictive performance of the final score was the predefined clinical phase ("complicated" vs. "uncomplicated"), which summarizes the presence of manifest organ involvement of the lungs, heart, or liver. Of note, some parameters of the complicated phase, such as arterial partial pressure of oxygen (PaO 2 ) and pericardial effusion, were acquired by indication (e.g., if an echocardiography or arterial blood gas analysis was performed, but not routinely). Therefore, for phase assignment, these do not have to be taken into account in the absence of an indication for the respective measurement. Serum urea, likely as a measure of kidney involvement, was an important predictor and outperformed creatinine previously for mortality. 20, 25 This predictor potentially summarizes both preexisting chronic kidney disease as a risk factor (Williamson et al. 26 ; Figure S1B ) and acute kidney injury (AKI) due to COVID-19 as organ involvement (also stable in RSF Boruta; Figure S1B ). Different mechanisms of AKI in COVID-19 patients have been observed, including indirect involvement, such as cardiorenal syndrome, direct virusinduced injury, and immunological causes such as complement activation. 27, 28 Differentiating the type of acute kidney involvement in COVID-19 patients may provide further insights and refine risk stratification in future analyses. Overall, our score, despite being limited to five predictors and applying a point system, compared favorably to more complex prediction models. 17, 20 We suggested a threshold for patients with an increased risk of critical disease at ≥17 points, based on the modified Youden's J. At this threshold, we obtained a positive likelihood ratio of threefold while retaining a good negative predictive value of 94%-95%. Different cut-offs may be considered based on the application and local circumstances (e.g., different local ratios of critical disease per case, and travel time to the next hospital in case of deterioration in an outpatient setting). The graphs provided in Figure 3 for sensitivity/specificity and PPV/NPV (based on the prevalence in the validation and test data sets) as well as in Figure S2 for absolute risk prediction may assist in determining such thresholds. Our study had several limitations. The LEOSS registry is anonymized, and continuous parameters are categorized, thus potentially reducing the predictive performance of laboratory measures. As a real-world data set, given the heterogeneity of clinical procedures across centers, our analysis had to compensate for missing values. This typically reduces the predictive performance of the respective variables and the probability that they pass the stability selection criteria. Therefore, some predictors may have been underestimated or missed. Our analysis was limited to predicting disease progression with information obtained at the time of the first positive SARS-CoV-2 testing (typically occurring during presentation at the medical facility), without considering the dynamics of the predictors. The days since the onset of symptoms (uncomplicated phase) to the diagnosis were included as a variable; however, the stability criteria were not met. In addition, there were differences between the validation and the test data set, with the latter having a higher proportion of patients diagnosed in the uncomplicated phase (suggesting earlier diagnosis, possibly due to expanded testing capacities after the first wave). Nevertheless, the score exhibited similar or better performance in the test set. This indirect evidence suggests that the application of our score may be valid for time points after diagnosis (or initial presentation), such as if the patient's condition or laboratory values deteriorate. Further studies are required to evaluate its suitability in such settings. No information on patient race/ethnicity was available for this analysis, and it may be assumed that the distribution follows that in the German population and represents largely Caucasians, which may limit generalizability. External validation in different patient populations is therefore required, also with regard to socioeconomic factors and local standards of care. Extensive information on comorbid conditions for study participants was available. Although some passed the criteria in RSF stability selection, none passed the RF stability criteria. However, more predictors (24 vs. 5) did not improve the overall predictive performance. This suggests that the increased risk due to these comorbidities may already be reflected by the remaining five predictors (collinearity), thereby relieving the need for inclusion in the score. However, this may not hold true for less common comorbidities, as the overall prediction improvement will be low for low prevalence predictors, even if they strongly affect the patients suffering from these comorbidities. A score based on the total population, as T A B L E 5 Score characteristics at the selected cut-off of ≥17 presented here, may underestimate high-risk constellations due to rare comorbidities, such as specific cancers or autoimmune diseases/ immunosuppressive treatments. To our knowledge, this limitation applies to most, if not all, available COVID-19 prognosis scores derived from the total population. Unfortunately, these patients may deteriorate rapidly. It is therefore important to establish the additional risk for such rare conditions in addition to the score used in future studies. The LEOSS registry was supported by the German Centre for Infection Research and the Willy Robert Pitzer Foundation. We express our deep gratitude to all study teams supporting the LEOSS study. The LEOSS study groups who contributed at least 5 per mille to the analyses of this study: University Hospital Freiburg (Siegbert Hospital Ingolstadt (Stefan Borgmann) Bundeswehr Hospital Koblenz University Hospital Tübingen (Siri Goepel), Municipal Hospital Karlsruhe Clinic Munich Sophien and Hufeland Clinic Weimar (Jessica Rüddel) Malteser Hospital St. Franziskus-Hospital Flensburg (Milena Milovanovic), Hospital Fulda (Philipp Markart) Spinner reports grants, personal fees, and nonfinancial support from Gilead Sciences Cilag, personal fees from Formycon, other from Aperion, other from Eli Lilly, during the conduct of the study AbbVie, personal fees from MSD, grants and personal fees from GSK/ViiV Healthcare outside the submitted work. Dr. Rüthrich reports grants from the IZKF outside the submitted work University of Bristol Vehreschild: Initiation and leading of LEOSS Developing and maintaining LEOSS. Stanislas Werfel Stanislas Werfel: Machine learning and statistical analyses, generation of tables and figures and manuscript preparation. Carolin E. M. Jakob: Data management, extraction, and additional statistical analyses. Uwe Heemann and Jochen Schneider: Data interpretation and critical revision of the manuscript Acquisition of data; all authors revised and approved the final version of the manuscript A novel coronavirus from patients with pneumonia in China Covid-19 compared to other pandemic diseases Back to the future: lessons learned from the 1918 influenza pandemic Potential association between COVID-19 mortality and health-care resource availability First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS) Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19 Fast Unified Random Forests for Survival, Regression, and Classification (RF-SRC). R package, version 2.9 Random forest missing data algorithms Missing value imputation in highdimensional phenomic data: imputable or not, and how? Feature selection with the Boruta package Using random forest to learn imbalanced data Random survival forests Significance testing in ridge regression for genetic data The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19 Machine learning to predict mortality and critical events in COVID-19 positive New York City patients: a cohort study Prediction model and risk scores of ICU admission and mortality in COVID-19 A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score Early prediction of mortality risk among patients with severe COVID-19, using machine learning Mortality Analyses-Johns Hopkins Coronavirus Resource Center. Accessed Prediction models for covid-19 outcomes Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe A validated, real-time prediction model for favorable outcomes in hospitalized COVID-19 patients Factors associated with COVID-19-related death using OpenSAFELY Management of acute kidney injury in patients with COVID-19 COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup Additional Supporting Information may be found online in the supporting information tab for this article.